| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2011 , Vol 53 , Num 3
FORMULATION AND EVALUATION OF PACLITAXEL NIOSOME FOR ITS IMPROVED ANTI-CANCER ACTIVITY
Department of Pharmaceutics, Periyar College of Pharmaceutical Sciences, Tiruchirappalli, Tamil Nadu, India
Viewed :
16191
-
Downloaded :
11135
The present work was to formulate Paclitaxel niosomes and evaluate for its in vitro cytotoxic studies using HEP-2 and HELA-human cancer cell lines. Drug-excipients interaction study revealed that there was no interaction between the drug and excipients. Formulations made with span 60 was the most satisfactory with the entrapment 97.0%; particle size 800-850 nm; the release was found to be 95.6% after 17 h and compared the LD50 with the standard formulation Taxol. Effects of volume of organic solvent, surfactant and cholesterol ratio were also studied. The stability study results revealed that the prepared formulation was stable in the stress condition.
Keywords :
PACLITAXEL, NIOSOME, CANCER CELL, HEP-2, HELA